Secondary Logo

Journal Logo

Arginine therapy in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes

Ikawa, Masamichia,b; Povalko, Nataliyac,d; Koga, Yasutoshic

Current Opinion in Clinical Nutrition and Metabolic Care: January 2020 - Volume 23 - Issue 1 - p 17–22
doi: 10.1097/MCO.0000000000000610
PROTEIN, AMINO ACID METABOLISM AND THERAPY: Edited by Rajavel Elango and Alessandro Laviano

Purpose of review We would like to inform clinicians that the systematic administration of oral and intravenous L-arginine is therapeutically beneficial and clinically useful for patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), when they maintain plasma arginine concentration at least 168 μmol/l.

Recent findings MELAS is associated with endothelial dysfunction by decreased plasma L-arginine, nitric oxide (NO), and cyclic guanosine monophosphate. Endothelial dysfunction is also evident using flow-mediated vasodilation measurement by high-resolution Doppler echocardiography in the forearm artery in patients with MELAS. L-arginine is known to be an important precursor of NO to normalize the endothelial function in MELAS. In our clinical trial followed by 7 years follow-up study, the systematic administration of L-arginine to patients with MELAS significantly improved the survival curve of patients compared with natural history. Maintaining plasma arginine concentration at least 168 μmol/l may prevent the ictuses through the putative pathophysiologic mechanism and optimal normalization of endothelial dysfunction.

Summary Neither death nor bedriddenness occurred during the 2-year clinical trials, and the latter did not develop during the 7-year follow-up despite the progressively neurodegenerative and eventually life-threatening nature of MELAS. Therapeutic regimen of L-arginine on MELAS may be beneficial and clinically useful for patient care with MELAS.

aDepartment of Advanced Medicine for Community Healthcare, Faculty of Medical Sciences

bBiomedical Imaging Research Center, University of Fukui, Fukui

cDepartment of Pediatrics and Child Health, Kurume University Graduate School of Medicine, Kurume, Japan

dInstitute of Fundamental Medicine and Biology, OpenLab Gene and Cell Technology, Kazan Federal University, Kazan Respublika Tatarstan, Russia

Correspondence to Yasutoshi Koga, MD, PhD, Department of Pediatrics and Child Health, Kurume University Graduate School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan. Tel: +81 942 31 7565; fax: +81 942 38 1794; e-mail:

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Back to Top | Article Outline


Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is a progressively neurodegenerative and eventually life-threatening mitochondrial disorder that causes anatomohistopathological and clinical findings [1]. An A-to-G transition mutation at nucleotide position 3243 in mitochondrial DNA (m.3243A>G) is the most common cause of this syndrome [2]. MELAS is distinguishably characterized by the sudden, transient, and recurrent development of stroke-resembling symptoms (headache, nausea/vomiting, visual disturbance/visual field abnormalities, seizures, and impaired consciousness: ictus), with the distribution of brain lesions that are incongruent to the usual vascular territories [3]. The primary cause for stroke-like episodes (SLE) in patients with MELAS, whether mitochondrial cytopathy, angiopathy, or both, remains controversial.

We reported that MELAS is associated with endothelial dysfunction using endothelial-dependent vasodilatation methods by a high-resolution doppler echocardiography [4]. Because patients with MELAS have defective respiratory chain enzyme activities, a high NADH/NAD+ ratio inhibits the nitric oxide (NO) synthetase reaction to cause a decreased production of NO at the endothelial cells or smooth muscle cells in the artery. In addition, asymmetrical dimethyl-arginine (ADMA), a risk factor of ischemic heart disorders, was relatively increased in patients with MELAS [5], which may lead to a negative effect on the endothelial NO synthetase activity. Indeed, decreased NO metabolite concentrations during SLE and lower NO synthesis rate were observed in patients with MELAS [5–8]. If hyperactive cytochrome c oxidase (COX) may decrease the regional NO concentration, all of the above scenarios lead to the segmental vasodilatation defect especially in the segment of strongly SDH-reactive blood vessel (SSV) regions in the cerebral artery or arterioles. These findings suggest that endothelial dysfunction because of NO deficiency is involved in the pathogenesis of SLE [9▪,10,11]. Low plasma concentration of L-arginine, a potent donor of NO, observed in patients with MELAS [5,8] supports the hypothesis and indicates the therapeutic potential of L-arginine on SLE.

Using L-arginine, we evaluated the potential at acute phase treatment by L-arginine infusion to cure the symptoms associated with SLE [4,5,12], and for prevent the SLE at intrinsic phase by L-arginine oral administration to decrease the severity of SLE, as the OL-MELAS Research Study[13▪].

Box 1

Box 1

Back to Top | Article Outline


The OL-MELAS Research is a 9-year clinical study, which integrated the pooled data from two, 2-year, phase III, prospective, multicenter, open-label clinical trials of oral and intravenous L-arginine in patients with juvenile-onset or adult-onset MELAS; the research was conducted at 10 medical institutions in Japan, in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The protocols were approved by the institutional review board at each site. Oral L-arginine and intravenous L-arginine were purchased commercially. The clinical trials were registered at Center for Clinical Trials, Japan Medical Association (registry numbers: JMACTR-IIA00023 and JMACTR-IIA00025). We compared the results of 9-year clinical study with nationwide epidemiologic study on this patient group available in Japan, which revealed the natural course of patients with MELAS [13▪].

Back to Top | Article Outline


In the clinical trial of oral L-arginine, before–after analysis revealed no statistically significant difference in the MELAS stroke scale, mitochondrial disease severity scores, or migraine severity scores. Namely, L-arginine therapy failed to achieve the endpoints. Nevertheless, the P value was 0.0549 in changes in the MELAS stroke scale, indicating a tendency of oral L-arginine to improve symptoms [13▪].

Regarding the efficacy of intravenous L-arginine, furthermore, the improvement rates of headache and nausea/vomiting at 2 h after completion of the initial intravenous administration were 25.0% (2/8) and 50.0% (3/6; P = 1.0000 each), respectively. Therefore, the statistical hypothesis that ‘the rate of improvement is greater than 30%’ could not be tested for these co-primary endpoints [13▪].

In the clinical trial of intravenous L-arginine study, the primary endpoints could not be achieved. We speculate that the extended window for intravenous administration from ‘3 h’ in our previous clinical study [5] to ‘6 h’ in the present clinical trial might have disadvantageously attenuated the pharmacologic effects of intravenous L-arginine. Indeed, L-arginine infusion during the hyperacute phase of SLE in MELAS may significantly improve the symptoms, and also completely protect the progression of neuroimaging change from transient to permanent brain atrophy [12] (Fig. 1).



Back to Top | Article Outline


At the completion of the 2-year clinical trials, both the bedriddenness and mortality rates were 0% despite the progressively neurodegenerative and eventually life-threatening nature of MELAS. At the completion of 7-year follow-up, the bedriddenness rate remained to be 0%; in contrast, the mortality rates of patients with juvenile-onset or adult-onset MELAS were 22.2 and 0.0% in patients with interictal MELAS and were 12.5 and 50.0% in patients with acute MELAS. The 9-year survival of patients who were treated with oral and intravenous L-arginine is significantly improved with those seen in the natural course of MELAS who did not get treated with L-arginine [5] (Fig. 2). Consequently, the ictuses developed at a plasma arginine concentration of 167 μmol/l or below are recognized in our clinical trials [13▪].



Back to Top | Article Outline


In addition to our OL-MELAS research, the eligibility criteria of which included patients carrying m.3243A>G, Ganetzky et al.[14▪] conducted a retrospective analysis of the therapeutic efficacy of intravenous L-arginine for SLE in nine pediatric patients harboring mitochondrial DNA mutations or nuclear DNA mutations except for m.3243A>G. Significant therapeutic benefit of L-arginine therapy was observed in these patients as well, which suggests that treatment with L-arginine is also favorable in patients with various genetic causes. Other clinical studies of L-arginine supplement therapy for MELAS have been done in different countries [15–21], and showed the improvement of the severity of the disease progression in MELAS.

Additionally, several case studies showing the therapeutic efficacy of L-arginine on SLE have been reported. Especially, Hovsepian et al.[22] performed magnetic resonance spectroscopy (MRS) to access the metabolic change in a SLE lesion of patients with MELAS before and after intravenous L-arginine therapy. Serial MRS showed decreased lactate peak and increased N-acetyl aspartate concentration (i.e. neuronal density) after treatment, which corresponded with clinical improvement.

Back to Top | Article Outline


The recent progress of molecular imaging with positron emission tomography (PET) and magnetic resonance imaging (MRI) has shed light on the pathophysiological process of SLE and the pharmacological effects of L-arginine.

Brain MRI and single-photon emission computed tomography (SPECT) imaging usually exhibit cerebral hyperemia, vasodilatation, and vasogenic edema because of mitochondrial angiopathy in acute lesions of SLE. In addition, arterial spin labeling (ASL) perfusion MRI clearly shows serial changes in cerebral perfusion related to the disease activity of SLE. Interestingly, we discovered regional cerebral hyper perfusion on ASL imaging in the preclinical phase of SLE in some patients with MELAS [23] (Fig. 3). These hyperperfused areas developed into acute lesions at the clinical onset of SLE, suggesting that subclinical SLE may have already occurred several months prior to the clinical onset. Because L-arginine can accommodate endothelial dysfunction (i.e. mitochondrial angiopathy), L-arginine therapy is expected to prevent the progression to evident SLE.



In addition to a therapeutic effect on mitochondrial angiopathy as a precursor of NO, L-arginine has a facilitative effect on tricarboxylic acid (TCA) cycle metabolism (i.e. mitochondrial cytopathy) via a conversion to α-ketoglutarate. Our previous study using 11C-acetate PET showed that intravenous administration of L-arginine enhanced TCA cycle kinetics in patients with mitochondrial cardiomyopathy carrying m.3243A>G [24]. The dual pharmacological effects of L-arginine on both mitochondrial angiopathy and cytopathy may have improved the long-term prognosis of patients with MELAS.

Back to Top | Article Outline


The OL-MELAS Research is therapeutically unique in the following achievements: a) specification of the plasma arginine concentration (trough level: 168 μmol/L) at which L-arginine can prevent an ictus that may cause irreversible brain damage, or bedriddeness in the worst case; b) presentation of ‘0%’ in the bedriddenness rate during the strict systematic administration of oral and intravenous L-arginine in the 2-year clinical trials; and c) the obvious suppression and modest retardation of disease progression at the ends of 2-year clinical trials and 7-year follow-up, respectively [13▪]. The L-arginine therapy is listed in the recent review of patient care standards for primary mitochondrial disease [25▪].

Back to Top | Article Outline


We would like to thank Dr Eisuke Inoue for his statistical analysis in the study.

Back to Top | Article Outline

Financial support and sponsorship

This study was funded by the Ministry of Health, Labour and Welfare of Japan (H14-Shouni-006) and Center for Clinical Trials, the Japan Medical Association Center (CCT-B-1803, CCT-C-2001).

Back to Top | Article Outline

Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline


Papers of particular interest, published within the annual period of review, have been highlighted as:

  • ▪ of special interest
  • ▪▪ of outstanding interest
Back to Top | Article Outline


1. Koenig MK, Emrick L, Karaa A, et al. Recommendations for the management of stroke-like episodes in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. JAMA Neurol 2016; 73:591–594.
2. Finsterer J. Mitochondrial metabolic stroke: phenotype and genetics of stroke-like episodes. J Neurol Sci 2019; 400:135–141.
3. Finsterer J, Wakil SM. Stroke-like episodes, peri-episodic seizures, and MELAS mutations. Eur J Paediatr Neurol 2016; 20:824–829.
4. Koga Y, Akita Y, Junko N, et al. Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology 2006; 66:1766–1769.
5. Koga Y, Akita Y, Nishioka J, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005; 64:710–712.
6. Hanff E, Kayacelebi A, Mariotti A F, et al. Analytical challenges in the assessment of NO synthesis from L-arginine in the MELAS syndrome. Int J Cardiol 2017; 234:141–142.
7. Hanff E, Kayacelebi AA, Herrmann C, et al. The l-arginine/NO pathway in the MELAS syndrome: an insufficiently explored and controversial research area. Int J Cardiol 2017; 229:27.
8. El-Hattab AW, Emrick LT, Hsu JW, et al. Impaired nitric oxide production in children with MELAS syndrome and the effect of arginine and citrulline supplementation. Mol Genet Metab 2016; 117:407–412.
9▪. El-Hattab AW, Almannai M, Scaglia F. Arginine and citrulline for the treatment of MELAS syndrome. J Inborn Errors Metab Screen 2017; 5.

The recent review by El-Hattab et al. provides a useful overview of the pharmacological effects of L-arginine on SLE.

10. Finsterer J, Zarrouk-Mahjoub S. A beneficial effect of l-arginine for stroke-like episodes is currently unsupported. Mol Genet Metab Rep 2018; 15:67–68.
11. Ganetzky RD, Falk MJ. Microvascular endothelial dysfunction in mitochondrial stroke-like episodes supports use of intravenous l-arginine. Mol Genet Metab Rep 2018; 15:74.
12. Kitamura M, Yatsuga S, Abe T, et al. L-Arginine intervention at hyper-acute phase protects the prolonged MRI abnormality in MELAS. J Neurol 2016; 263:1666–1668.
13▪. Koga Y, Povalko N, Inoue E, et al. Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research. J Neurol 2018; 265:2861–2874.

The recent article from Koga et al. provides important evidence that L-arginine has long-term therapeutic efficacy on SLE in MELAS patients.

14▪. Ganetzky RD, Falk MJ. 8-year retrospective analysis of intravenous arginine therapy for acute metabolic strokes in pediatric mitochondrial disease. Mol Genet Metab 2018; 123:301–308.

The recent article from Ganetzky et al. provides the therapeutic benefit of L-arginine therapy in patients harboring various genetic etiologies.

15. Liu XQ, Shen SQ, Yang GC, et al. Mitochondrial A3243G mutation causes mitochondrial encephalomyopathy in a Chinese patient: Case report. Medicine (Baltimore) 2019; 98:e15534.
16. Sun X, Jiang G, Ju X, et al. MELAS and macroangiopathy: a case report and literature review. Medicine (Baltimore) 2018; 97:e13866.
17. Wei Y, Cui L, Pen B. L-Arginine prevents stroke-like episodes but not brain atrophy: a 20-year follow-up of a MELAS patient. Neurol Sci 2019; 40:209–211.
18. Pérez Torre P, Acebrón-Herrera F, et al. Global cerebral involvement and L-arginine use in a patient with MELAS syndrome. Neurologia 2018; S0213-4853:30151–30158.
19. Tsikas D. Measuring NO production rate from l-arginine in MELAS by mass spectrometry-based approaches: GC-MS or LC-MS/MS? Int J Cardiol 2018; 256:6.
20. Murakami H, Ono K. MELAS: mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes. Brain Nerve 2017; 69:111–117.
21. Fryer RH, Bain JM, De Vivo DC. Mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS): a case report and critical reappraisal of treatment options. Pediatr Neurol 2016; 56:59–61.
22. Hovsepian DA, Galati A, Chong RA, et al. MELAS: Monitoring treatment with magnetic resonance spectroscopy. Acta Neurol Scand 2019; 139:82–85.
23. Ikawa M, Yoneda M, Muramatsu T, et al. Detection of preclinically latent hyperperfusion due to stroke-like episodes by arterial spin-labeling perfusion MRI in MELAS patients. Mitochondrion 2013; 13:676–680.
24. Arakawa K, Kudo T, Ikawa M, et al. Abnormal myocardial energy-production state in mitochondrial cardiomyopathy and acute response to L-arginine infusion. C-11 acetate kinetics revealed by positron emission tomography. Circ J 2010; 74:2702–2711.
25▪. Parikh S, Goldstein A, Karaa A, et al. Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med 2017; 19: doi: 10.1038/gim.2017.107.

The recent article from Parikh S. et al. provides the updated review of patient care standards for mitochondrial disorders.


endothelial dysfunction; L-arginine; mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS); stroke-like episodes; therapeutic regimen

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.